Literature DB >> 4075539

Oestrogen-related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles.

M Dowsett, S L Attree, S S Virdee, S L Jeffcoate.   

Abstract

Previous studies have identified no consistent change in sex hormone binding globulin (SHBG) levels during normal menstrual cycles. This is despite marked cyclical changes in plasma oestradiol concentration, and the observation that SHBG level increases in pregnancy, and after administration of exogenous gonadotrophin or synthetic oestrogens. The level of SHBG was measured in 19 normal females at 2 d intervals from day -8 to +10 where the preovulatory peak of oestradiol was designated as occurring on day 0. SHBG levels increased by a mean 15% +/- 4 (SEM) between the follicular and luteal phases (P less than 0.001) and this was due entirely to an increment between day 0 and +2. The change in SHBG levels was correlated with the change in oestradiol levels between days -8 and 0 (P less than 0.001). Fifty-six infertile patients were also studied. Twenty-seven received Pergonal alone whilst the other 29 received Pergonal after a preceding 5 d on Clomid. In both groups peak preovulatory oestradiol levels were greater than 3 times higher than in normal cycles. SHBG levels showed no change in the follicular phase but rose markedly during the luteal phase. These increases were significantly correlated with peak preovulatory oestradiol concentration but showed no relationship with mid-luteal progesterone concentration. We conclude that supranormal levels of oestradiol cause marked increases in SHBG binding capacity and increases in SHBG level of a lower order occur shortly after the preovulatory peak of oestradiol in the normal menstrual cycle.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4075539     DOI: 10.1111/j.1365-2265.1985.tb00228.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Effect of estrogens on prolactin secretion in transsexual subjects.

Authors:  H H Goh; S S Ratnam
Journal:  Arch Sex Behav       Date:  1990-10

2.  Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men.

Authors:  M Dowsett; P Lloyd
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Serum and follicular fluid sex hormone-binding globulin in stimulated and unstimulated cycles.

Authors:  I Phocas; T Mantzavinos; A Sarandakou; F Dimitriadou; P A Zourlas
Journal:  J Assist Reprod Genet       Date:  1995-07       Impact factor: 3.412

4.  Genesis of breast cancer in Japanese: a possible relationship between sex hormone binding globulin (SHBG) and serum lipid components.

Authors:  O Takatani; T Okumoto; H Kosano
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

5.  Effects of prednisolone on sex hormone binding globulin during primary endocrine treatment of advanced breast cancer.

Authors:  D Y Wang; R D Rubens; G M Clark; J W Moore; R D Bulbrook
Journal:  Breast Cancer Res Treat       Date:  1988-04       Impact factor: 4.872

6.  Associations of Serum Levels of Sex Hormones in Follicular and Luteal Phases of the Menstrual Cycle with Breast Tissue Characteristics in Young Women.

Authors:  Linda Linton; Monica Taylor; Sheila Dunn; Lisa Martin; Sonia Chavez; Greg Stanitz; Ella Huszti; Salomon Minkin; Norman Boyd
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

7.  Absence of Effect of Intravaginal Miconazole, Clindamycin, Nonoxynol-9, and Tampons on the Pharmacokinetics of an Anastrozole/Levonorgestrel Intravaginal Ring.

Authors:  Rüdiger Nave; Stefan Klein; André Müller; Xinying Chang; Joachim Höchel
Journal:  J Clin Pharmacol       Date:  2017-08-07       Impact factor: 3.126

8.  Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.

Authors:  M J Millward; B M Cantwell; M Dowsett; J Carmichael; A L Harris
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

9.  Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.

Authors:  R C Stein; M Dowsett; D C Cunningham; J Davenport; H T Ford; J C Gazet; E von Angerer; R C Coombes
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

10.  Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones.

Authors:  J W Moore; T J Key; R D Bulbrook; G M Clark; D S Allen; D Y Wang; M C Pike
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.